Timing correction: Axon is scheduled to report after the market close today, Wednesday, August 5, 2026, with its earnings call at 5:00 p.m. ET—not tomorrow.
Axon enters Q2 with exceptional operating momentum. In Q1, revenue grew 34% year over year to $807 million, its ninth consecutive quarter above 30% growth, prompting management to raise 2026 revenue-growth guidance to 30%–32% from 27%–30%. The fundamental setup remains strong: cloud/AI adoption is accelerating, Dedrone is scaling materially faster than initial expectations, international demand is broadening, and the company continues to add new enterprise and 911-market vectors.
The issue into earnings is less whether Axon can post strong growth and more whether results and forward commentary can clear an elevated investor bar. AXON closed at $607.24 on August 4, up roughly 57% since the May 6 Q1 release and about 15% since the July 31 close. That positioning makes the guide, bookings indicators, margin trajectory, and management’s commentary on AI and counter-drone demand at least as important as the headline revenue/EPS result.
Q2 2025 revenue was $669 million, up 33% year over year. Maintaining Axon’s current full-year growth framework would be directionally consistent with Q2 revenue around $869 million–$882 million—though seasonality, the revenue-recognition cadence of large contracts, and hardware shipment timing can create meaningful variation.
The core setup is favorable:
Investor focus: A result around the guide-implied range may not be sufficient if it comes with deceleration in ARR, net retention, bookings, or the fastest-growing newer categories. Conversely, another material beat with a guide raise would reinforce the argument that Axon’s growth runway is broadening rather than maturing.
AI is now central to the Axon thesis. Management said in Q1 that:
The key question is whether the AI Era Plan is continuing to convert from initial contracts and bookings into recurring revenue at the pace implied by Q1 ARR growth. Investors should look for evidence that new capabilities—such as Draft One, Axon Assistant, Axon Vision, Guardian, Form One, Brief One, and Justice tools—are increasing bundle adoption, customer spend, and contract rewrites.
What would be constructive: ARR acceleration, NRR remaining near or above 125%, commentary that AI is expanding beyond early adopters, and confirmation that new AI features support future price increases or contract upgrades.
Risk: AI revenue may remain small relative to the attention it receives, while deployment and professional-services requirements could pressure software-and-services margins in the near term.
Dedrone and counter-drone products are the most visible new hardware growth driver. In Q1, management described bookings growth of more than 500% year over year and said demand exceeded its ability to deliver product. The business is benefiting from growing concern around critical infrastructure, data centers, enterprises, large public events, federal customers, and international markets.
The Q2 call should clarify whether this demand has remained broad-based after a very strong Q1—and whether supply has kept pace.
However, Dedrone is also dilutive to hardware margin at its current scale. Platform Solutions is Axon’s lower-margin connected-device category, and Q1 connected-devices gross margin declined 140 basis points year over year to 48.7%, reflecting tariffs and higher Dedrone mix.
Questions for management - Is counter-drone demand still supply constrained? - How much Q2 growth came from counter-drone versus the core TASER/body-camera franchise? - Are event deployments converting into permanent city, federal, or enterprise infrastructure contracts? - What is the medium-term gross-margin opportunity as the business scales and software attach increases?
The bull case is that Dedrone is not merely an event-driven product cycle, but a durable platform opening doors across Axon’s state/local, federal, international, and enterprise markets.
Management maintained its 25.5% adjusted EBITDA margin target for 2026 after posting 25.0% in Q1. It expects operating leverage in the second half to offset:
Q1 adjusted gross margin was 61.6%, down 200 basis points year over year, while software-and-services adjusted gross margin fell 190 basis points to 75.8%. The software-only gross margin remained above 80%, an encouraging indicator that the underlying SaaS economics remain attractive.
Takeaway: Q2 need not show immediate margin expansion, but investors will want confidence that mix pressure is transitory or manageable and that second-half operating leverage remains credible. A reduction in the EBITDA-margin target would be a significant negative surprise.
Q1 free cash flow was negative $55 million, primarily because Axon deliberately increased inventory to support rapidly growing hardware demand, including Dedrone. Management maintained full-year expectations for:
The inventory build is strategically understandable: Axon’s hardware has long product cycles and management does not want supply constraints to cap revenue growth. But the scale matters. Inventory rose to $408 million at March 31 from $342 million at year-end, while Axon ended Q1 with roughly $1.0 billion of net debt, driven largely by acquisitions and investments.
Q2 cash conversion could remain uneven—Q2 2025 also had negative free cash flow—but management needs to demonstrate that working-capital investment is controlled and that the full-year cash-flow target remains intact.
| Metric | Q1 2026 | Q2 2025 | What to watch in Q2 2026 |
|---|---|---|---|
| Revenue growth | 34% | 33% | Sustained 30%+ growth; upside versus elevated expectations |
| Software & Services growth | 35% | 39% | ARR conversion, premium-plan adoption, AI contribution |
| Connected Devices growth | 33% | 29% | TASER 10 / Body 4 durability and Platform Solutions mix |
| ARR | $1.49B, +35% YoY | $1.18B, +39% YoY | Continued growth and evidence of AI-driven expansion |
| Net revenue retention | 125% | 124% | Stability near 125% would validate land-and-expand |
| Future contracted bookings | $14.3B, +44% YoY | $10.7B, +43% YoY | Growth, large-deal cadence, and delivery visibility |
| Adjusted EBITDA margin | 25.0% | 25.7% | Progress toward 25.5% FY target |
| Free cash flow | $(55)M | $(115)M | Inventory/working-capital normalization and FY confidence |
Axon has one of the stronger fundamental setups in growth technology: high recurring-revenue expansion, strong retention, a large contracted-bookings base, durable core-device demand, and several increasingly credible adjacencies. The Q2 report should determine whether the company can extend its remarkable 30%-plus growth streak while preserving the margin and cash-flow framework required to justify investor expectations.
The most important signals tonight are likely to be 2026 guidance, ARR/NRR and bookings momentum, Dedrone demand and margin commentary, and confidence in second-half cash conversion—more than the headline EPS figure, which can be affected by stock compensation, strategic-investment marks, and other non-core items.